Market Cap (In USD)
4.81 Million
Revenue (In USD)
-
Net Income (In USD)
-15.44 Million
Avg. Volume
32.6 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.2-4.313
- PE
- -
- EPS
- -
- Beta Value
- 0.314
- ISIN
- US1429221039
- CUSIP
- 142922103
- CIK
- 1842939
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ms. Kendra Bracken-Ferguson
- Employee Count
- -
- Website
- https://www.carmellrx.com
- Ipo Date
- 2021-09-23
- Details
- Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
More Stocks
-
BGAVFBravada Gold Corporation
BGAVF
-
NUGNLivento Group, Inc.
NUGN
-
SCP
-
002331
-
DARE
-
CLPHFCLP Holdings Limited
CLPHF
-
SIEGY
-
BBXIABBX Capital, Inc.
BBXIA